GBA Presents: RADIO SAVANT-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2022.

  1. Ted, Van Did you buy the Jan 120's?
     
    #11311     Dec 20, 2022
  2. I agree that the selling is exaggerated but the Market is always right. I only trust a few like BA, MRNA, Abbv, PFE, MRK, NVO, JPM, LLY, TJX and Rost.
     
    #11312     Dec 20, 2022
  3. No, NYSE stocks love to gap and come back down. ULTA(Nas) had more explosive earnings and they’re down 10%+ after a wonderful Q. Nice trade Stoney!

    Edited: AEO, CHWY($48 to $39 on a great Q.)and GPS($12-$15 to $12)same thing.
     
    #11313     Dec 20, 2022
  4. :) Nike price target raised to $138 from $127 at Morgan Stanley 06:49 NKE
     
    #11314     Dec 21, 2022
    TrailerParkTed likes this.
  5. The Children rejoice at Christmas time-!

    OH Van-! WE Did It!!!>$$$$$$$$$$:fistbump:
    NKE NIKE, Inc.


    $103.210.16(+0.16%)11:00 AM 12/20/22
    NYSE |$USD |Pre-Market:$114.92+11.71(+11.35%)<----- OMG!

    What will the options do 200%?:p



     
    #11315     Dec 21, 2022
  6. WKEY WISeKey International Holding AG Possible gummy....

    $1.750.03(+1.74%)10:32 AM 12/20/22
    NASDAQ |$USD |Pre-Market:$1.86+0.11(+6.29%)<------------
     
    #11316     Dec 21, 2022
  7. GVA Granite Construction Incorporated

    $35.25// Extremely slow mover still like.
     
    #11317     Dec 21, 2022
  8. 2nd GUMMY IDEA-> ZYME

    Jazz to continue with its rights to Zymeworks' zanidatamab in key markets 07:33 JAZZ, ZYME Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the U.S., Europe and Japan, pursuant to the license and collaboration agreement entered into in October 2022. The decision to exercise this option follows positive top-line clinical data from HERIZON-BTC-01, a pivotal trial in previously treated HER2-amplified biliary tract cancers, which demonstrated that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response as assessed by independent central review. The median duration of response was 12.9 months. The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
     
    #11318     Dec 21, 2022
  9. Zymeworks Inc. (ZYME)
    NasdaqGS - NasdaqGS
    7.08+0.29 (+4.27%)
    At close: December 20 04:00PM EST
    7.34 +0.26 (+3.67%)<-------------------
    Pre-Market: 07:59AM EST
     
    #11319     Dec 21, 2022
  10. Like a merry Santa I have come back to bless the children with winnings. Everyone knows Nike and all Children are aboard this trade! All EIGHT! >>>> I guess that's what happens when you lay the trade out early and prepare everyone.

    The children deserve this and so they shall enter the Christmas season in good shape.

    Now I must pull anchor and head to Ct.-
    I will check in at 2:00 pm.

     
    #11320     Dec 21, 2022